Abstract: The present invention provides a stabilized pharmaceutical suspension of carisbamate for pediatric and adult use. More particularly, the suspension is stabilized with hypromellose (HFMC) to prevent crystal growth of the suspended particles and to prevent re-crystallization of the drug product with change in polymorphic form.
Abstract: Piperidine compounds and pharmaceutically useful salts thereof, a pharmaceutical composition including an effective amount of the racemic or enantiomerically enriched piperidine compounds to treat gastrointestinal diseases, and a method of treating gastrointestinal diseases in a mammal are provided.
Type:
Grant
Filed:
June 9, 2017
Date of Patent:
December 4, 2018
Assignee:
SK BIOPHARMACEUTICALS CO., LTD.
Inventors:
Coo-Min Chung, Hyung-Jin Jun, Jin-Sung Kim, Hiu-Ho Kim, Hye-Kyung Min, Yong-Gil Kim, Jong-Gil Choi, Hongwook Kim
Abstract: The present invention relates to a method for treating or preventing obesity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds. The invention further relates to methods for reducing body weight and/or reducing food intake in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds.
Type:
Grant
Filed:
May 12, 2017
Date of Patent:
October 23, 2018
Assignees:
Jazz Pharmaceuticals International III Limited, SK Biopharmaceuticals Co., Ltd.
Inventors:
Moise A. Khayrallah, Gary Bream, Stephen E. Butts
Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.
Type:
Grant
Filed:
July 31, 2017
Date of Patent:
October 16, 2018
Assignee:
SK BIOPHARMACEUTICALS CO., LTD.
Inventors:
Chun Eung Park, Young Koo Jang, Yong Je Shin, Ji Yeon Kim, Seung Mo Ham, Yong Gil Kim, Hye Kyung Min, Soo Bong Cha, Hyo Jun Jung, Ju Young Lee, Seung Nam Han, Jin Yong Chung, Eun Ju Choi, Chan Mi Joung, Jong Sil Park, Ji Won Lee, Nahm Ryune Cho, Eun Ju Ryu, Cheol Young Maeng
Abstract: The present invention relates to the use of compounds of the invention for treatment and/or prevention of fatigue, including fatigue associated with diseases or treatments.
Type:
Grant
Filed:
September 16, 2016
Date of Patent:
June 19, 2018
Assignee:
SK Biopharmaceuticals Co., Ltd.
Inventors:
Moise A. Khayrallah, Gary Bream, Stephen E. Butts, Susan Marie Melnick, Duncan Taylor
Abstract: A pyridone derivative compound and a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof, and a preventive or therapeutic pharmaceutical composition for cognitive disorders that includes the pyridone derivative compound or a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof.
Type:
Grant
Filed:
January 18, 2016
Date of Patent:
June 5, 2018
Assignee:
SK BIOPHARMACEUTICALS CO., LTD.
Inventors:
Cheol Young Maeng, Young Koo Jang, Su Bong Cha, Hye Won Shin, Chan Mi Joung, Eun Jung Yi
Abstract: There is provided a transnasal anticonvulsive pharmaceutical composition including a poorly soluble anticonvulsant. The anticonvulsive pharmaceutical composition comprising a poorly soluble anticonvulsant as an active component, which is transnasally spray-administered, comprises diethylene glycol monoethyl ether and fatty acid ester, wherein the fatty acid ester is selected from the group consisting of caprylocaproyl polyoxylglyceride, isopropyl palmitate, oleoyl polyoxylglyceride, sorbitan monolaurate 20, methyl laurate, ethyl laurate, and polysorbate 20. Also, the anticonvulsive pharmaceutical composition comprising a poorly soluble anticonvulsant as an active component, which is transnasally spray-administered, comprises diethylene glycol monoethyl ether, fatty acid ester, methylpyrrolidone, water and alcohol. Therefore, the transnasal anticonvulsive pharmaceutical composition may be useful to highly enhance the bioavailability of the poorly soluble anticonvulsant.
Type:
Grant
Filed:
October 23, 2013
Date of Patent:
May 8, 2018
Assignee:
SK Biopharmaceuticals Co., Ltd.
Inventors:
Myoung-Ki Baek, Jae-Hoon Jo, Hye-Jin Chang
Abstract: The invention is directed to a method of treating bipolar disorder in a subject, comprising administering a therapeutically effective amount of a carbamate compound, or pharmaceutically acceptable salt or amide thereof.
Abstract: The present disclosure provides a compound represented by Formula (I) and a pharmaceutically acceptable salt which are effective as a dopamine reuptake inhibitor and a method of using the compound: wherein X is independently halo, alkyl, alkoxy or nitro; m is 0, 1, 2, 3 or 4; n is 1 or 2; R1 and R2 are independently H— or alkyl; R3 is H—, alkyl or aralkyl; and R4 is H— or aryl.
Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.
Type:
Grant
Filed:
February 25, 2016
Date of Patent:
August 29, 2017
Assignee:
SK BIOPHARMACEUTICALS CO., LTD.
Inventors:
Chun Eung Park, Young Koo Jang, Yong Je Shin, Ji Yeon Kim, Seung Mo Ham, Yong Gil Kim, Hye Kyung Min, Soo Bong Cha, Hyo Jun Jung, Ju Young Lee, Seung Nam Han, Jin Yong Chung, Eun Ju Choi, Chan Mi Joung, Jong Sil Park, Ji Won Lee, Nahm Ryune Cho, Eun Ju Ryu, Cheol Young Maeng
Abstract: The present invention relates to a solid dispersion characterized in that it comprises carbamic acid 3-(4-benzyloxy-phenyl)-isoxazol-5-ylmethyl ester as an active ingredient and a water-soluble polymer having a glass transition temperature lower than the melting point of the active ingredient as a carrier, and it is prepared via melt extrusion. The solid dispersion of the present invention remarkably increases the solubility and dissolution rate of the active ingredient which is an insoluble drug to efficiently improve the bioavailability when it is orally administered.
Abstract: The invention is directed to a method of treating fibromyalgia syndrome in a subject, comprising administering a therapeutically effective amount of a carbamoyl compound, or pharmaceutically acceptable salt thereof.
Abstract: Piperidine compounds and pharmaceutically useful salts thereof, a pharmaceutical composition including an effective amount of the racemic or enantiomerically enriched piperidine compounds to treat gastrointestinal diseases, and a method of treating gastrointestinal diseases in a mammal are provided.
Type:
Grant
Filed:
August 26, 2016
Date of Patent:
June 13, 2017
Assignee:
SK BIOPHARMACEUTICALS CO., LTD.
Inventors:
Coo-Min Chung, Hyung-Jin Jun, Jin-Sung Kim, Hiu-Ho Kim, Hye-Kyung Min, Yong-Gil Kim, Jong-Gil Choi, Hongwook Kim
Abstract: The invention is directed to a method of treating attention-deficit/hyperactivity disorder (ADHD) in a subject, comprising administering a therapeutically effective amount of a carbamoyl compound, or pharmaceutically acceptable salt thereof.
Abstract: The present invention relates to a method for treating or preventing obesity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds. The invention further relates to methods for reducing body weight and/or reducing food intake in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds.
Type:
Grant
Filed:
December 1, 2015
Date of Patent:
May 16, 2017
Assignees:
Jazz Pharmaceuticals International III Limited, SK Biopharmaceuticals Co., Ltd.
Inventors:
Moise A. Khayrallah, Gary Bream, Stephen E. Butts
Abstract: The invention is directed to a method of treating bipolar disorder in a subject, comprising administering a therapeutically effective amount of a carbamate compound, or pharmaceutically acceptable salt or amide thereof.
Abstract: This invention is directed to a method of treating Excessive daytime Sleepiness (EDS) in a subject, comprising the step of administering a therapeutically effective amount of a compound of Formula (I): Formula (I) or a pharmaceutically acceptable salt or ester thereof wherein Rx is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms; x is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3; R1 and R2 can be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, arylalkyl, cycloalkyl of 3 to 7 carbon atoms; R1 and R2 can be joined to form a 5 to 7-membered heterocycle substituted with a member selected from the group consisting of hydrogen, alkyl, and aryl groups, wherein the cyclic
Type:
Grant
Filed:
August 6, 2014
Date of Patent:
March 28, 2017
Assignee:
SK Biopharmaceuticals Co., Ltd.
Inventors:
Abdallah Ahnaou, Wilhelmus H. I. M. Drinkenburg, Joseph Palumbo, Jonathan Sporn
Abstract: Piperidine compounds and pharmaceutically useful salts thereof, a pharmaceutical composition including an effective amount of the racemic or enantiomerically enriched piperidine compounds to treat gastrointestinal diseases, and a method of treating gastrointestinal diseases in a mammal are provided.
Type:
Grant
Filed:
January 17, 2014
Date of Patent:
March 14, 2017
Assignee:
SK BIOPHARMACEUTICALS CO., LTD.
Inventors:
Coo-Min Chung, Hyung-Jin Jun, Jin-Sung Kim, Hui-Ho Kim, Hye-Kyung Min, Yong-Gil Kim, Jong-Gil Choi, Hongwook Kim
Abstract: The present invention relates to a method of treating cataplexy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds.
Type:
Grant
Filed:
May 9, 2016
Date of Patent:
March 7, 2017
Assignees:
Jazz Pharmaceuticals International III Limited, SK Biopharmaceuticals Co., Ltd.
Inventors:
Moise A. Khayrallah, Gary Bream, Stephen E. Butts
Abstract: The present invention relates to a solid dispersion characterized in that it comprises carbamic acid 3-(4-benzyloxy-phenyl)-isoxazol-5-ylmethyl ester as an active ingredient and a water-soluble polymer having a glass transition temperature lower than the melting point of the active ingredient as a carrier, and it is prepared via melt extrusion. The solid dispersion of the present invention remarkably increases the solubility and dissolution rate of the active ingredient which is an insoluble drug to efficiently improve the bioavailability when it is orally administered.